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Abstract
Introduction: Disulfiram has been claimed to be useful in cocaine addiction
therapy, its efficacy being attributed to dopamine-beta-hydroxylase (DBH) inhi-
bition. Our previous results indicate that disulfiram and the selective DBH inhi-
bitor nepicastat increase extracellular dopamine (DA) in the rat medial
prefrontal cortex (mPFC), and markedly potentiated cocaine-induced increase.
Concomitantly, in rats with cocaine self-administration history, cocaine-seeking
behavior induced by drug priming was prevented, probably through overstimu-
lation of D1 receptors due to the DA increase. The present research was aimed
at studying the neurochemical mechanisms originating the enhanced DA
release. Methods: Noradrenergic system ablation was attained by intracere-
broventricular (i.c.v.) administration of the neurotoxin anti-DBH-saporin
(aDBH-sap). DA, noradrenaline (NA), and DOPAC were assessed by HPLC
after ex vivo tissue extraction or in vivo microdialysis. Control and denervated
rats were subjected to microdialysis in the mPFC and caudate nucleus to evalu-
ate the effect of nepicastat–cocaine combination on extracellular DA levels and
their regulation by a2-adrenoceptors. Results: Fifteen days after neurotoxin or
its vehicle administration, tissue and extracellular NA were reduced to less than
2% the control value, while extracellular DA was increased by approximately
100%. In control rats, nepicastat given alone and in combination with cocaine
increased extracellular DA by about 250% and 1100%, respectively. In dener-
vated rats, nepicastat slightly affected extracellular DA, while in combination
with cocaine increased extracellular DA by 250%. No differences were found in
the caudate nucleus. Clonidine almost totally reversed the extracellular DA ele-
vation produced by nepicastat–cocaine combination, while it was ineffective in
denervated rats. Conclusions: This research shows that the increase of extracellu-
lar DA produced by nepicastat alone or in combination with cocaine was prevented
by noradrenergic denervation. The results indicate that nepicastat enhances DA
release from noradrenergic terminals supposedly by removing NA from a2-autore-
ceptors. In addition to the inhibition of DA uptake, the latter mechanism may
explain the synergistic effect of cocaine on nepicastat-induced DA release.
Introduction
Dopamine-beta-hydroxylase (DBH), the enzyme that con-
verts dopamine (DA) to noradrenaline (NA), is a promis-
ing target for pharmacotherapies targeting cocaine (George
et al. 2000; Petrakis et al. 2000; Carroll et al. 2004; Kosten
et al., 2013), alcohol dependence (Johansson 1992;
Colombo et al. 2014), and eating disorders (Zaru et al.
2013; Farci et al. 2015).
Disulfiram, which in addition to aldehyde dehydroge-
nase (ALDH) (Lipsky et al. 2001) also inhibits DBH
(Goldstein et al. 1964; Musacchio et al. 1966), was
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initially used in patients simultaneously abusing alcohol
and cocaine, based on the rationale that it would deter
alcohol use and thus eliminate alcohol priming effect on
cocaine use (Higgins et al. 1993; Carroll et al. 2000). Sub-
sequently disulfiram was found to be even more effective
in reducing the frequency and amount of cocaine use in
nonalcoholic cocaine-dependent patients, suggesting that
it directly impacts the behavioral response to cocaine
(Hameedi et al. 1995; McCance-Katz et al. 1998a,b;
George et al. 2000; Carroll et al. 2004).
The efficacy of disulfiram in the treatment of cocaine
dependence has been attributed to an increase in brain
dopamine (DA) resulting from DBH inhibition, which in
turn corrects the “hypodopaminergia” present in cocaine-
dependent subjects, purportedly responsible for loss of
control and compulsive drug use (Petrakis et al. 2000;
Volkow et al. 2009). Alternatively, it has been suggested
that excessive DA release following cocaine use after
disulfiram treatment may be associated with anxiety and
dysphoria, rather than euphoric response, resulting in
reduced cocaine use (McCance-Katz et al. 1998a,b; Kosten
et al. 2002).
However, as besides ALDH and DBH, disulfiram also
inhibits a series of copper-containing enzymes and differ-
ent esterases, including plasma cholinesterase involved in
cocaine metabolism (Hameedi et al. 1995; Baker et al.
2007), its mechanism of action in clinical application
remains unclear.
Experimental investigations have provided an impor-
tant contribution toward clarifying this problem. Consis-
tent with clinical results obtained, Schroeder et al. (2010)
have shown in rats that disulfiram inhibits cocaine-
primed reinstatement of cocaine-seeking behavior after
extinction, with this effect being reproduced by nepicas-
tat, a selective DBH inhibitor, devoid, unlike disulfiram,
of ALDH inhibitory property (Stanley et al. 1997). These
authors suggested that DBH inhibitors, by reducing NA
formation, would decrease noradrenergic drive onto mid-
brain dopaminergic neurons, which is essential for
cocaine-induced DA release and consequent reinstatement
of cocaine-seeking behavior (Schank et al. 2006; Gaval-
Cruz and Weinshenker 2009; Schroeder et al. 2010, 2013).
Accordingly, the same authors predicted that DBH inhibi-
tors should attenuate dopaminergic firing and cocaine-in-
duced release in the nucleus accumbens and prefrontal
cortex.
However, at variance with these assumptions, empirical
evidence from our laboratory indicates that both disulfi-
ram and nepicastat produce, as expected, not only a wide-
spread reduction in tissue NA content and release, but
they also increase DA release in the mPFC, an effect
markedly potentiated by cocaine. Moreover, both DBH
inhibitors were also found to increase, although modestly,
DA release in the nucleus accumbens and to not modify
cocaine-induced DA release in this region. It should be
highlighted that, to the best of our knowledge, the effect
of DBH inhibitors on the firing of meso-cortico-limbic
dopaminergic neurons has not been tested to date. To
explain our results we suggested that DBH inhibitors
cause a lack of NA at release-inhibiting a2-autoreceptors,
leading to unrestrained release of DA, substituting for
NA, from noradrenergic terminals.
The present study intended to provide direct evidence
that DBH inhibitors increase DA release from noradrener-
gic terminals in the mPFC. To this aim, we verified
whether the effect of nepicastat on DA release was modi-
fied after selective central noradrenergic denervation pro-
duced by an anti-DBH-antibody conjugated to the
ribosomal toxin saporin (aDBH-sap) that has the ability,
after intraventricular injection, to effectively and selec-
tively destroy the majority of central noradrenergic neu-
rons (Wrenn et al. 1996; Rohde and Basbaum 1998).
Methods
All experiments were approved by the local Ethical Com-
mittee and performed according to the European Com-
munities Council Directive of 24 November 1986 (86/
609/EEC) in compliance with the “Principles of Labora-
tory Animal Care” guidelines. Male Sprague Dawley rats
(Harlan Italy, S. Pietro al Natisone, Italy), weighing 175–
200 g on arrival, were housed in groups of five per cage
for at least 7 days before use, under standard conditions
of temperature and humidity and artificial light from
8 AM to 8 PM; food and water were available ad libitum.
Experiments were conducted from 9 AM to 5 PM. A total
of 73 animals were used.
Noradrenergic system ablation was achieved by admin-
istration of the selective and potent neurotoxin aDBH-
sap. To this aim, rats were deeply anesthetized with
Equithesin (containing, per 100 mL, 0.97 g pentobarbital,
2.1 g MgSO4, 4.25 g chloral hydrate, 42.8 mL propylene
glycol, 11.5 mL 90% ethanol; 5 mL/kg, i.p.) and placed in
a Kopf stereotaxic apparatus. The skull was exposed and a
hole was drilled directly into the lateral ventricle (AP
1.0, L  1.5 from the bregma, V 4.3 from skull, coor-
dinates according to Paxinos and Watson 1997) to allow
the administration of immunotoxin (n = 35) or vehicle
(n = 38) solutions. aDBH immunotoxin was diluted in a
sterile-filtered phosphate-buffered saline (vehicle:
140 mmol/L NaCl, 3 mmol/L KCl, 2 mmol/L KH2PO4,
10 mmol/L Na2HPO4, pH 7.4) and injected intracere-
broventricularly (i.c.v.) in a volume of 5 lL with a 10 lL
syringe operated by a CMA/100 microinjection pump
(CMA Microdialysis, Stockholm, Sweden) at a rate of
1 lL/min over 5 min, followed by a 2-min pause before
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slowly withdrawing the needle. Injections were randomly
distributed into either the left or right lateral ventricles.
Control rats received the corresponding volume of vehi-
cle, alone or containing either saporin or a nonspecific
mouse IgG conjugated with saporin in equimolar concen-
trations to the immunotoxin. Preliminary experiments
indicated that tissue and extracellular DA and NA values
from vehicle-treated rats were no different from values
obtained from rats injected i.c.v. with vehicle containing
saporin or IgG-saporin, or from intact rats. Rats treated
with vehicle were therefore used as controls. Rats were
given antibiotic therapy (enrofloxacin; Bayer HealthCare,
Shawnee Mission, KS) for 5 days and allowed to recover
in their home cages for 15–18 days; they were then
stereotaxically implanted with vertical microdialysis
probes (membrane AN 69-HF, Hospal-Dasco, Bologna,
Italy; cutoff 40,000 Daltons, 4-mm active membrane
length), in the mPFC (AP +3.0, L  0.6, V 6.5 from
the bregma, according to the coordinates of Paxinos and
Watson 1997), under Equithesin anesthesia. The day after
probe implantation, artificial cerebrospinal fluid
(147 mmol/L NaCl, 4 mmol/L KCl, 1.5 mmol/L CaCl2,
1 mmol/L MgCl2, pH 6–6.5) was pumped through the
dialysis probes at a constant rate of 1.1 lL/min via a
CMA/100 microinjection pump (Carnegie Medicine,
Stockholm, Sweden) in freely moving animals, and dialy-
sate samples were collected every 20 min. NA, DA, and
DOPAC were simultaneously analyzed by HPLC with
electrochemical detection, by HPLC systems equipped
with 3.0 9 150 mm C18 (3.5 l) symmetry columns
(Waters, Milan, Italy), maintained at 40°C by Series 1100
thermostats (Agilent Technologies, Waldbronn, Ger-
many), and ESA Coulochem II detectors (Chelmford,
MA). The mobile phase consisted of 80 mmol/L
Na2HPO4, 0.27 mmol/L EDTA, 0.6 mmol/L sodium octyl
sulfate, 8% methanol, 3% acetonitrile, pH 2.8 with
H3PO4, delivered at 0.3 mL/min; the Coulochem analyti-
cal cell first electrode was set at +200 mV, the second at
200 mV. Quantification was performed by recording
the second electrode signal. Under these conditions, NA
and DA detection limits (signal-to-noise ratio 3:1) were
0.3 pg per injection on column. In all aDBH-sap-lesioned
rats, extracellular NA levels were lower than the HPLC
detection limit. On completion of testing, rats were sacri-
ficed by Equithesin overdose, the brains removed and sec-
tioned by a cryostat (Leica CM3050 S) in 40-lm thick
coronal slices to verify locations of dialysis probes. No
animal was found with errant location of the device.
To evaluate tissue contents of NA, DA, and DOPAC,
rats were sacrificed by decapitation (n = 18 denervated
and 17 control rats); brains were rapidly removed and
placed on a brain cutting block maintained on ice. The
mPFC was dissected out from 2-mm slices, immediately
frozen on dry ice, and stored at 80°C until processing
for catecholamine content. Briefly, tissues were weighed,
homogenized by sonication in 0.1 mol/L HClO4 (1:20
weight tissue per solvent volume), centrifuged at 10,000g,
the supernatant filtered using microspin centrifuge tubes
(0.22-lm nylon filter), and directly injected into the
HPLC column under analytical conditions as described
for microdialysis experiments. Data were expressed as pg
neurotransmitter per mg tissue.
Drugs
Immunotoxin aDBH-sap, IgG-saporin, and saporin were
purchased from Advanced Targeting System (San Diego,
CA). Nepicastat was a gift from Biotie Therapies (Basel,
Switzerland), clonidine was purchased from Tocris (Bris-
tol, UK), cocaine hydrochloride from Macfarlan Smith
Ltd. (Edinburgh, UK). Nepicastat was used at the dose of
50 mg/kg per mL i.p., dissolved by sonication in DMSO/
water (50/50); clonidine (0.15 mg/kg) and cocaine
(10 mg/kg) were dissolved in sterile water. All drugs were
administered i.p. in a volume of 1 mL/kg weight.
Statistical analysis
To compare catecholamine levels in denervated and con-
trol animals, significances of intergroup differences were
calculated using the unpaired two-tailed Student’s t-test
with Welch’s correction. To evaluate the effect of drug
administration versus baseline level, one-way ANOVA
for repeated measure with Bonferroni’s post hoc test
was applied. To compare the drug effects between the
two treatment groups (vehicle vs. aDBH-sap), repeated
measure two-way ANOVA with Sidak’s multiple com-
parison test as post hoc was applied. Statistical signifi-
cance was set at P < 0.05. Statistical analysis employed
Prism 6.0c program (GraphPad Software Inc., San
Diego, CA).
Results
As shown in Tables 1 and 2, the intraventricular adminis-
tration of aDBH-sap reduced mPFC tissue and extracellu-
lar NA content to less than 2% with respect to control
rats, while it failed to modify tissue DA content and
increased extracellular DA by about 100%, with respect to
control rats. In denervated rats, tissue and extracellular
DOPAC levels were modestly reduced and unchanged,
respectively, with respect to control rats, indicating that
denervation-induced extracellular DA accumulation is the
result of a reduced DA retrieval from extracellular spaces
rather than increased DA synthesis and metabolism in
dopaminergic neurons.
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Consistent with previous observations, in control rats
nepicastat, at the dose of 50 mg/kg, increased extracellular
DA to about 350% the basal value, with this increase per-
sisting at 2 h after treatment (Fig. 1).
In contrast, in denervated rats nepicastat effect was
modest and short lasting: extracellular DA levels increased
to 150% the baseline at 20 min and returned to baseline
within 60 min (Fig. 1). Statistical analysis by two-way
RM-ANOVA, with treatment (Vehicle, aDBH) as
between-subject factor and time (using the samples col-
lected after nepicastat treatment) as within-subject
repeated measure factor, indicated a significant effect of
treatment (F1,9 = 5.62; P < 0.05) and time (F5,45 = 4.92;
P < 0.002). Post hoc Sidak’s multiple comparisons test
evidenced that nepicastat effect was significantly different
between control and lesioned animals at time points 140,
160 (P < 0.05), and 180 min (P < 0.01).
As Figure 2 shows, in control rats the coadministration
of nepicastat and cocaine (50 and 10 mg/kg i.p., respec-
tively) produced a striking 1200% increase of extracellular
DA, a much higher increase than the sum of the effect of
each compound given alone. In denervated rats the drug
combination increased extracellular DA to about 350%,
roughly the sum of the effects of cocaine and nepicastat
observed in these animals (Fig. 2). Two-way ANOVA
resulted in a significant effect of treatment (F1,7 = 8.07;
P < 0.05) and time (F5,35 = 4.30; P < 0.005).
As Figure 3 shows, denervation also reduced the effect of
cocaine given alone. At the dose of 10 mg/kg, cocaine
increased extracellular DA to approximately 350% in con-
trol rats, but only to 200% in denervated rats. Statistical
analysis by two-way ANOVA, with treatment (Vehicle,
aDBH) as between-subject factor and time as within-sub-
ject repeated measure factor, indicated a significant effect
of treatment (F1,8 = 7.92; P < 0.05) and time (F5,40 = 3.36;
P < 0.02).
Table 2. Extracellular catecholamine and DOPAC levels in the medial
prefrontal cortex of rats treated with aDBH-sap or vehicle.
Treatment Noradrenaline Dopamine DOPAC
Vehicle 3.56  0.24 1.50  0.09 186.40  29.60
a-DBH-sap ND1 3.22  0.29* 211.12  29.86
Extracellular noradrenaline, dopamine, and DOPAC basal levels in the
medial prefrontal cortex of rats injected i.c.v. with antidopamine-b-hy-
droxylase saporin (aDBH-sap) or vehicle. Results are means  SEM of
values obtained from 21 control and 17 lesioned rats, and are
expressed as pg per sample.
1Noradrenaline levels were lower than the detection limit in all
lesioned rats.
*P < 0.0001 vs. vehicle (two-tailed, Welch-corrected unpaired Stu-
dent’s t-test).
Figure 1. Effect of nepicastat (50 mg/kg, i.p.) on extracellular
dopamine levels in the medial prefrontal cortex of control (n = 6) and
aDBH-sap treated (n = 5) rats. Results are the mean  SEM expressed
as percentage of mean basal level. Arrow indicates the time of
nepicastat administration. Black symbols indicate P < 0.05 with
respect to basal values (one-way RM-ANOVA with Bonferroni’s test as
post hoc); asterisks indicate time points significantly different between
the two treatment groups (two-way RM-ANOVA, with Sidak’s
multiple comparisons test as post hoc). *P < 0.05; **P < 0.01.
Table 1. Tissue catecholamine and DOPAC content in the medial pre-
frontal cortex of rats treated with aDBH-sap or vehicle.
Treatment Noradrenaline Dopamine DOPAC
Vehicle 473.6  16.9 98.8  4.7 31.2  1.5
a-DBH-sap 5.6  1.3** 85.4  9.6 24.5  2.7*
Values are expressed as pg/mg tissue, and given as the mean  SEM
of 18 rats, sacrificed 16–19 days after the intraventricular infusion of
the vehicle or the antidopamine-b-hydroxylase saporin (aDBH-sap).
**P < 0.0001 vs. vehicle; *P < 0.05 (two-tailed, unpaired Student’s
t-test with Welch correction).
Figure 2. Effect of nepicastat (50 mg/kg, i.p.) and cocaine (10 mg/kg
i.p.) coadministration on extracellular dopamine levels in the medial
prefrontal cortex of vehicle (n = 5) and aDBH-sap (n = 4) treated rats.
Results are the mean  SEM expressed as percentage of mean basal
level. The first arrow indicates the time of nepicastat administration,
the second indicates cocaine administration. Asterisks indicate
significantly different time points between treatment groups (two-way
RM-ANOVA, with Sidak’s multiple comparisons test as post hoc).
*P < 0.05.
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However, since DA basal levels in denervated rats were
100% higher than in control rats, DA increase produced
by cocaine in control and denervated rats were recalcu-
lated as net of baseline absolute amounts of DA released.
As Figure 4 shows, cocaine increased extracellular DA by
the same degree in control and denervated rats. In control
rats the combination of nepicastat and cocaine produced
an increase of 70 pg (cumulative effect during the 2 h
collection period after cocaine injection), whereas in den-
ervated rats the increase was of about 30 pg. One-way
ANOVA indicated a very significant treatment effect
(F3,14 = 13.1, P < 0.001); the net increase produced by
nepicastat–cocaine association resulted to be significantly
different between control and denervated animals
(Tukey’s multiple comparisons test: P < 0.001), but nepi-
castat plus cocaine-induced increase was not significantly
different from cocaine-induced increase in denervated
animals (Tukey’s multiple comparisons test: P = ns).
On the other hand, denervation failed to modify the
effect of cocaine on extracellular DA in the caudate
nucleus, with cocaine increasing extracellular DA to
approximately 250% in both intact and denervated rats
(Fig. 5). Two-way ANOVA indicated a highly significant
effect of time (F5,35 = 13.0; P < 0.0001), but no signifi-
cant effect of treatment (F1,7 = 5.15; P > 0.05).
Consistent with previous observations, systemic admin-
istration of the a2-adrenoceptor agonist clonidine
(0.15 mg/kg, i.p.) produced a rapid and complete reversal
of the extracellular DA elevation produced by nepicastat–
cocaine combination (Fig. 6A). In contrast, in denervated
rats treated with nepicastat–cocaine combination, cloni-
dine failed to significantly modify extracellular DA levels
(Fig. 6B). Two-way ANOVA evidenced in both groups a
significant effect of treatment (control: F1,4 = 39.8,
P < 0.005; lesioned: F1,5 = 8.13, P < 0.05) and time (con-
trol: F4,16 = 19.5, P < 0.0001; lesioned: F4,20 = 9.06,
P < 0.001). Post hoc Sidak’s multiple comparison test
indicated as significantly different time points from 180
to 240 for control rats and 220 to 240 for aDBH-lesioned
animals.
Discussion
Consistent with previous studies showing that the anti-
DBH-saporin efficiently and selectively destroys the
majority of CNS noradrenergic neurons after intraventric-
Figure 3. Effect of cocaine (10 mg/kg, i.p.) on extracellular
dopamine levels in the medial prefrontal cortex of vehicle (n = 6) and
aDBH-sap treated (n = 4) rats. Results are the mean  SEM expressed
as percentage of mean basal level. Arrow indicates the time of
cocaine administration. Asterisks indicate significantly different time
points between the two treatment groups (two-way RM-ANOVA,
with Sidak’s multiple comparisons test as post hoc). *P < 0.05.
Figure 4. Effect of cocaine, alone or associated with nepicastat, on
dopamine output in intact (control) and denervated (aDBH-sap) rats.
Dopamine output is expressed as cumulative amount of dopamine
above the baseline, measured during six consecutive dialysate samples
after cocaine treatment. Each bar represents the mean  SEM of 4–6
rats. *P < 0.01 with respect to corresponding column in aDBH-sap
treated rats (one-way ANOVA, with Sidak’s multiple comparisons test
as post hoc).
Figure 5. Effect of cocaine (10 mg/kg, i.p.) on extracellular
dopamine levels in the caudate nucleus of vehicle (n = 5) and aDBH-
sap treated (n = 4) rats. Results are the mean  SEM expressed as
percentage of mean basal level. Arrow indicates the time of cocaine
administration.
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ular administration (Wrenn et al. 1996; Rohde and Bas-
baum 1998), we found that the toxin depleted tissue and
extracellular NA by almost 98% in the mPFC, but failed
to reduce tissue DA, and actually increased extracellular
DA by approximately 100% above the level measured in
control rats.
DOPAC concentration was reduced in tissue but not in
dialysate from lesioned animals, as expected consequence
of decreased intracellular DA catabolism due to loss of
noradrenergic neurons. These findings are in apparent
contrast with our former hypothesis that the majority of
extracellular DA in the mPFC originates from noradrener-
gic terminals (Devoto et al. 2001; Devoto and Flore
2006). However, DA elevation present after denervation
may be explained by a loss of NA transporter (NET), the
principal mechanism of DA uptake in the mPFC (Car-
boni et al. 1990; Pozzi et al. 1994; Moron et al. 2002),
the possible sprouting of dopaminergic fibers compensat-
ing for loss of noradrenergic innervation, and loss of NA
at putative release-inhibiting a2-heteroreceptors on
dopaminergic terminals.
A major outcome of this study is the finding that nora-
drenergic denervation prevented almost completely nepi-
castat-induced DA release, and also drastically reduced
extracellular DA accumulation produced by cocaine–nepi-
castat association in the mPFC, but failed to do so in the
caudate nucleus, where dopaminergic innervation is
prevalent over noradrenergic innervation.
Indeed, in control rats the coadministration of cocaine
and nepicastat produced a striking 12-fold increase of
extracellular DA, whereas in denervated rats the increase
was 30% that observed in intact rats. These results suggest
that the majority of extracellular DA released by nepicas-
tat given alone or in combination with cocaine originates
from noradrenergic terminals. This hypothesis may
explain why the magnitude of extracellular DA elevation
observed following administration of the DBH inhibitors
nepicastat or disulfiram was proportional to the ratio of
noradrenergic to dopaminergic innervation in the brain
region examined, being highest in the mPFC and occipital
cortex, modest in the nucleus accumbens and null in the
caudate nucleus (Devoto et al. 2012, 2014a).
To explain extracellular DA elevation after DBH inhibi-
tors, we postulated that DBH inhibition causes a lack of
NA at release-inhibiting a2-autoreceptors, leading to
unrestrained release of DA, instead of NA, from nora-
drenergic terminals in the mPFC (Devoto et al. 2012,
2014a). This hypothesis is supported by our previous
studies indicating that disulfiram-induced DA release in
the mPFC was reversed by locally infused tetrodotoxin or
by the a2-adrenoceptor agonist clonidine, systemically
injected or locally infused at nerve terminal level, but was
not further augmented by administration of the a2-
adrenoceptor antagonist RS 79948, consistent with the
hypothesis that autoreceptors were not occupied by NA
after DBH inhibition (Devoto et al. 2012). A lack of NA
at release-inhibiting a2-autoreceptors might contribute,
together with cocaine-induced blockade of DA clearance
from extracellular spaces, toward the synergistic potentia-
tion of nepicastat effect by cocaine.
Our results do not rule out the possibility that DA
released from dopaminergic terminals may contribute to
the effect produced by nepicastat. Indeed, a2-adrenocep-
tor immunoreactivity has been detected in the majority of
dopaminergic neurons in the ventral tegmental area (Lee
et al. 1998), suggesting the existence of release-inhibiting
a2-heteroreceptors on dopaminergic terminals in the
mPFC. However, the contribution of dopaminergic termi-
Figure 6. Effect of clonidine (0.15 mg/kg i.p.) on nepicastat plus cocaine administration (50 + 10 mg/kg i.p., respectively), on extracellular
dopamine levels in the medial prefrontal cortex of control (A) and aDBH-lesioned (B) rats. Results are the mean  SEM expressed as percentage
of mean basal level. The first arrow indicates the time of nepicastat administration, while the second indicates cocaine administration. Clonidine
was injected 20 min after cocaine (third arrow). Asterisks indicate significantly different time points between the two treatment groups (two-way
RM-ANOVA, with Sidak’s multiple comparisons test as post hoc). *P < 0.05.
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nals to nepicastat-induced DA output seems to be lower
than that of noradrenergic ones, since denervation, which
is expected to eliminate both NET and the presence of
NA at a2-adrenoceptors, including a2-heteroreceptors,
produced a rather modest increase of extracellular DA
when compared with the marked elevation previously
observed in intact rats, in which NET and a2-adrenocep-
tors were pharmacologically inactivated (Devoto et al.
2004).
Moreover, clonidine totally reversed extracellular DA
elevation produced by nepicastat–cocaine combination in
intact rats, but failed to reduce extracellular DA in dener-
vated rats, consistent with the hypothesis that clonidine
acts on a2-autoreceptors rather than a2-heteroreceptors at
dopaminergic terminals, although the possibility that den-
ervation might have altered the sensitivity of a2-adreno-
ceptors to clonidine cannot be dismissed.
Our results provide indirect support to the hypothesis
that DA normally released from noradrenergic terminals
may account for the major portion of extracellular DA in
the mPFC, and for most of extracellular DA in occipital,
parietal, and cerebellar cortices, where dopaminergic
fibers are scarce or absent (Devoto et al. 2001). Consis-
tent with these considerations, a recent study by Smith
and Greene (2012) indicates that noradrenergic fibers in
the hippocampus are the origin of DA released by amphe-
tamine, suggesting that DA from noradrenergic terminals
in hippocampus plays a key role in learning state and
potentially in addictive processes.
Irrespective of the source of DA in the mPFC released
by nepicastat and its coadministration with cocaine, the
elevation of extracellular DA poses the problem of its
physiological significance, specifically the suppressant
effect produced on cocaine-primed reinstatement of
cocaine seeking in rats, and its clinical anticocaine effect.
The accepted view that cocaine-primed reinstatement
of drug-seeking behavior is mediated by DA, possibly act-
ing on D1 receptors (Capriles et al. 2003; Kalivas and
McFarland 2003), is not in contrast to our hypothesis
that the suppressant effect of DBH inhibitors is due to an
excess of DA in the mPFC leading to a supranormal stim-
ulation of D1 receptor signaling in the dorsal m PFC
(Devoto et al. 2014b). Indeed we postulated that an opti-
mal level of D1 receptor stimulation is required for rein-
statement of drug seeking, while an excessive stimulation
leads to suppression of this behavior. This hypothesis is
consistent with previous researches that indicate an
inverted “U” shaped function for the D1 receptor stimu-
lation of neuronal activity in the mPFC and correlated
with cognitive performances (Vijayraghavan et al. 2007).
Further research should clarify whether DA release in the
mPFC might mediate the suppressant effect of nepicastat
or disulfiram on reinstatement of cocaine seeking triggered
by cues and stress other than by cocaine itself (Schroeder
et al. 2013). On the other hand, our results signal the possi-
ble risk that an excessive release of DA in subjects assuming
cocaine after treatment with nepicastat might precipitate
psychotic symptoms, as observed following disulfiram–co-
caine interaction (Cubells et al. 2000; Mutschler et al.
2009; Grau-Lopez et al. 2012). These considerations are of
considerable relevance as nepicastat is currently undergoing
Phase 2 development for cocaine dependence (ClinicalTri-
als.gov identifier: NCT01704196, A Multi-Center Trial of
Nepicastat for Cocaine Dependence).
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